FBR & Co Comments on Corium International Inc.’s FY2016 Earnings (CORI)

fbr-038-co-comments-on-corium-international-inc8217s-fy2016-earnings-cori.jpg

Corium International Inc. (NASDAQ:CORI) – Stock analysts at FBR & Co increased their FY2016 EPS estimates for Corium International in a note issued to investors on Tuesday. FBR & Co analyst E. White now forecasts that the firm will post earnings per share of ($1.53) for the year, up from their previous estimate of ($1.60). FBR & Co has a “Buy” rating and a $18.00 price target on the stock. FBR & Co also issued estimates for Corium International’s Q4 2016 earnings at ($0.30) EPS, FY2017 earnings at ($1.27) EPS and FY2018 earnings at ($1.17) EPS.
Corium International (NASDAQ:CORI) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Corium International had a negative return on equity of 158.38% and a negative net margin of 104.77%.
CORI has been the topic of several other reports. Zacks Investment Research cut Corium International from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Corium International in a report on Thursday, June 23rd. Finally, Leerink Swann restated a “buy” rating and issued a $14.00 price objective on shares of Corium International in a report on Wednesday, May 18th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $11.92.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/fbr-co-comments-on-corium-international-inc-s-fy2016-earnings-cori.html

Shares of Corium International (NASDAQ:CORI) traded up 0.3599% during midday trading on Friday, reaching $5.5499. The company’s stock had a trading volume of 20,900 shares. The firm’s market cap is $124.09 million. Corium International has a 12 month low of $3.14 and a 12 month high of $11.80. The company has a 50-day moving average price of $5.09 and a 200-day moving average price of $4.40.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Receive News & Ratings for Corium International Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Corium International Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "FBR & Co Comments on Corium International Inc.’s FY2016 Earnings (CORI)"

Leave a comment

Your email address will not be published.


*